poisar

Stocks · News reference

Lifeward Announces Publication Of Long-Term Study On User Experience Of Its ReWalk Personal Exoskeleton In 'Spinal Cord Series And Cases'

BenzingaBenzinga Newsdesk

Publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of the ReWalk® Personal Exoskeleton in individuals

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Global Walk Assist Robot Market Research Report and Strategic Forecast 2026-2031 | AI and Hybrid Wearables Expand Clinical and Home-Care Growth Opportunities

    The global walk assist robot market is projected to grow at a CAGR of 15.01% from 2024 to 2031, driven by AI/ML integration, hybrid wearable systems, rising stroke incidence, and an aging population. Key applications include neuro-rehabilitation, post-surgical rehabilitation, and elderly mobility assistance. North America leads with 39% market share, while Asia-Pacific shows sustained growth potential. High costs and regulatory challenges remain market restraints.

  2. SEC EDGARSEC EDGAR

    8-K filing — Lifeward Ltd. (LFWD)

    Filed: 2026-11-13 AccNo: 0001178913-26-005208 Size: 395 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

  3. Globenewswire IncLifeward Ltd.

    Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain

    An independent peer-reviewed study published in the Internet Journal of Allied Health Sciences and Practice demonstrates that individuals with chronic spinal cord injury using Lifeward's ReWalk personal exoskeleton showed significant improvements in daily activity performance, satisfaction, and reduced pain compared to wheelchair use. All 12 study participants successfully performed kitchen tasks while standing, 10 performed grooming tasks, and 8 reported improvements in bowel and bladder function. The findings support ReWalk's clinical value as Lifeward expands commercial distribution and reports 13% year-over-year sales growth to $2.5 million in Q2 2026.